Hikma Pharmaceuticals Plc (HIK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and Rest of the World (ROW). Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc (HIK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 16
Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 17
Venture Financing 18
Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18
Prognos Health Raises USD20.5 Million in Series C Financing 20
Partnerships 21
Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 21
Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 22
Hikma Pharma Forms Joint Venture With Midroc Pharma 23
Venture Life Enters into Distribution Agreement with Hikma Pharma 24
Licensing Agreements 25
Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 25
Hikma Pharma Enters into Licensing Agreement with Rovi 26
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 27
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 28
Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 29
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 30
Hikma Pharma Enters into Licensing Agreement with Octapharma 31
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 32
Hikma Pharma Enters into Licensing Agreement with Vitabiotics 33
Hikma Pharma Enters into Licensing Agreement with Azanta 34
Hikma Pharma Enters into Licensing Agreement with SK Chemicals 35
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 36
Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 37
Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 38
Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 39
Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 40
Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 41
Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 42
Debt Offering 43
Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43
Asset Transactions 44
Amphastar Pharma Acquires 14 ANDAs from Hikma Pharma for USD4 Million 44
Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 45
Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 46
Acquisition 47
Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 47
Hikma Pharma to Acquire EIMC United Pharma 49
Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 50
Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 52
Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 53
Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For US$42 Million 54
Hikma Pharmaceuticals Plc - Key Competitors 55
Hikma Pharmaceuticals Plc - Key Employees 56
Hikma Pharmaceuticals Plc - Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Joint Venture 58
Recent Developments 59
Financial Announcements 59
Aug 15, 2018: Hikma Pharmaceuticals: Half-year report 59
Mar 14, 2018: Hikma reports 2017 full year results 64
Aug 17, 2017: Hikma Delivers Stable Profitability and Strong Cash Generation In H1 and Maintains a Solid Balance Sheet 65
Mar 15, 2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency 66
Corporate Communications 67
Jun 04, 2018: Hikma Appoints Henriette Nielsen As Chief Transformation Officer 67
Feb 20, 2018: Sigurdur Olafsson appointed Chief Executive Officer of Hikma 68
Jan 15, 2018: Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific Officer and Global Head of R&D 69
Jun 26, 2017: Hikma Pharmaceuticals Announces Leadership and Organisational Changes to US Business 70
Other Significant Developments 71
May 03, 2017: Hikma Changes Registered Office 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List Of Tables


Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hikma Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 16
Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 17
Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18
Prognos Health Raises USD20.5 Million in Series C Financing 20
Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 21
Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 22
Hikma Pharma Forms Joint Venture With Midroc Pharma 23
Venture Life Enters into Distribution Agreement with Hikma Pharma 24
Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 25
Hikma Pharma Enters into Licensing Agreement with Rovi 26
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 27
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 28
Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 29
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 30
Hikma Pharma Enters into Licensing Agreement with Octapharma 31
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 32
Hikma Pharma Enters into Licensing Agreement with Vitabiotics 33
Hikma Pharma Enters into Licensing Agreement with Azanta 34
Hikma Pharma Enters into Licensing Agreement with SK Chemicals 35
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 36
Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 37
Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 38
Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 39
Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 40
Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 41
Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 42
Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43
Amphastar Pharma Acquires 14 ANDAs from Hikma Pharma for USD4 Million 44
Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 45
Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 46
Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 47
Hikma Pharma to Acquire EIMC United Pharma 49
Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 50
Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 52
Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 53
Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For US$42 Million 54
Hikma Pharmaceuticals Plc, Key Competitors 55
Hikma Pharmaceuticals Plc, Key Employees 56
Hikma Pharmaceuticals Plc, Subsidiaries 57
Hikma Pharmaceuticals Plc, Joint Venture 58

List Of Figures


Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

Amoxicillin and Clavulanate Potassium Global Market Review and Outlook by 14 Companies (SANDOZ, TEVA, Hikma Pharmaceuticals, Micro Labs, Aurobindo Pharma, Wockhardt, Hovid etc.), by Type (Tablets, Granules, Capsules, Suspension, Injection)

Amoxicillin and Clavulanate Potassium report is in-depth investigation for Global market. Amoxicillin and Clavulanate Potassium market was valued at USD XX million Global in 2018 and is forecasted to reach

USD 3000 View Report

Hikma Pharmaceuticals Plc (HIK) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer,

USD 250 View Report

Amoxicillin and Clavulanate Potassium Global Market Review and Outlook by 14 Companies (SANDOZ, TEVA, Hikma Pharmaceuticals, Micro Labs, Aurobindo Pharma, Wockhardt, Hovid etc.), by Type (Tablets, Granules, Capsules, Suspension, Injection)

Amoxicillin and Clavulanate Potassium report is in-depth investigation for Global market. Amoxicillin and Clavulanate Potassium market was valued at USD XX million Global in 2018 and is forecasted to reach

USD 3000 View Report

GW Pharmaceuticals Plc (GWPH) - Financial and Strategic SWOT Analysis Review

GW Pharmaceuticals Plc (GWPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available